Precipio

Update in progress

PRPO (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

Precipio, Inc. is a healthcare biotechnology company that develops and provides cancer diagnostic products, reagents, and services in the United States. It offers diagnostic blood cancer testing and a range of genetic diagnostic panels under its HemeScreen line. The company also provides IV-Cell, a proprietary culture medium for simultaneous growth of four hematopoietic cell lineages, plus biomarker testing and clinical project services for bio-pharma customers. Based in New Haven, Connecticut.

Company score

Sentiment: -0.31; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.41; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.38; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.20; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive